IntrOduCtIOn
Rheumatoid arthritis (RA) is an autoimmune disease characterised by inflammation of synovial joints, with a prevalence worldwide of 0.5%-1%. Environmental/non-genetic susceptibility factors account for up to 60% of the risk for developing RA 1 ; however, only a limited number of such factors have been identified. 2 3 Long-chain n-3 (also known as omega-3) polyunsaturated fatty acids (PUFA), especially eicosapentaenoic acid (EPA; 20:5 n-3) and docosahexaenoic acid (DHA; 22:6 n-3), have long been considered to have anti-inflammatory and immunomodulatory actions. 4 Neither n-3 nor n-6 (omega 6) series PUFA (each family is determined by the number of carbon atoms between the methyl end of the fatty acyl chain and the first doublebond) can be synthesised de novo by large animals and so they are considered essential. The main dietary form of n-3 PUFA in most humans is the plant-derived alpha-linolenic acid (ALA; 18:3 n-3). 5 ALA is metabolised by a series of desaturation and elongation steps to the longer chain EPA and DHA. This process of conversion into longer chain PUFA is poor in humans 6 and in direct competition with the desaturation and elongation of the considerably more abundant n-6 PUFA. Longer chain n-3 PUFAs can be synthesised by phytoplankton and are passed up the food chain through zooplankton to fish. Because of limited synthesis from ALA in humans, most EPA and DHA in the human body are of dietary origin, with marine foods such as deep sea fatty fish or fish oil supplements being particularly good sources. The parent n-6 PUFA is linoleic acid (LA; 18:2 n-6), which is more commonly obtained in the diet than any n-3 PUFA, with vegetable oils, especially sunflower, corn and soybean, being particularly good sources. Desaturation and elongation of LA give rise to longer chain n-6 PUFA such as arachidonic acid and gamma-linolenic acid. Although there is a widespread conception that n-6 PUFAs are proinflammatory, some data suggest an immunomodulatory potential.
and has shown efficacy in RA clinical trials. [10] [11] [12] While the observed effects of fish oil in established RA are Clinical and epidemiological research modest, the concept of a 'window of opportunity' in early disease suggests a greater potential for protective immunomodulation in the very earliest stages. Findings on the relationship between dietary intake of fish/fish oil and prevention of RA have been inconsistent. [13] [14] [15] [16] [17] It is usually assumed that any observable effects of fish intake are due to their long-chain n-3 PUFA content. One study reported that higher intake of n-3 PUFA, determined using food frequency questionnaire data, was associated with lower risk of RA. 18 However estimated dietary intakes of n-3 PUFA often correlate poorly with in vivo levels of these fatty acids, 19 20 which in turn are also influenced by endogenous processes including elongation, desaturation and β-oxidation. Erythrocyte membranes offer an attractive biomarker of PUFA status in vivo, and reflect dietary intake, uptake and endogenous metabolism over a period of at least 1 month. 19 Recently higher erythrocyte n-3 PUFA levels were found to be associated with a lower risk of RA-related autoantibodies in a population at risk of RA. 21 22 However, there are few data on erythrocyte membrane PUFA and risk of RA. We therefore sought to establish whether there were differences in erythrocyte membrane fatty acid profiles, as a biomarker of PUFA status, between individuals with pre-RA and matched controls in a nested case-control study, and to test the hypothesis that higher levels of long-chain n-3 PUFA are associated with lower risk of RA. As a proinflammatory state may exist prior to the clinical onset of RA, and conceivably might alter PUFA metabolism, we also analysed the relationship between PUFA levels and serum cytokines as a secondary outcome.
MetHOds study sample
The European Prospective Investigation into Cancer and Nutrition (EPIC) is a multicentre, pan-European prospective cohort study designed to investigate the association between diet and cancer, as well as other diseases, in apparently healthy populations. 23 We undertook a nested case-control study to investigate risk factors for RA, by identifying subjects who developed incident RA after enrolment (referred to here as pre-RA). These pre-RA cases were matched with controls among subjects enrolled in four EPIC cohorts: Naples, Turin and Ragusa in Italy, and Murcia in Spain. Potential RA cases were identified as previously described. 24 In brief, in Murcia, RA cases were identified by linkage with primary healthcare records (International Classification of Primary Care code L88) and prescriptions of disease-modifying antirheumatic drugs, and linkage using the International Classification of Diseases (ICD) codes with hospital discharge (ICD9: 714) and mortality databases (ICD10: M05 and M06). In Naples, RA cases were identified by linkage with hospital discharge databases and information from systematic telephone follow-up of participants. In Turin, RA cases were identified by linkage with hospital discharge databases and a drug prescription database with a disease-specific code. In Ragusa, cases were identified by linkage with hospital discharge databases. Identification of all RA cases was undertaken in 2011. All cases were then subsequently validated by medical record review to confirm a physician diagnosis of RA and to confirm date of diagnosis, as previously described. 24 Subjects with prevalent RA at the time of the blood sample were excluded from the analyses. The EPIC cohorts included in this study recruited subjects between 1992 and 1998. 23 Three controls were randomly selected from living cohort members and matched for every individual case by age at blood collection (±1 year), sex, centre, date (±2 months) and time (±3 hours) of baseline blood collection, and fasting status at blood collection (<3/3-6/>6 hours). There were erythrocyte samples available for 96 of the 103 pre-RA cases and 258 matched controls.
data collection
Baseline questionnaires collected detailed data on diet, 23 physical activity, medical history, smoking status, and sociodemographic and lifestyle factors (current and lifetime history). Level of education was defined as having (1) no education, (2) primary school, (3) technical or professional school and (4) higher education (including university degrees). Physical activity was estimated using the Cambridge Physical Activity Index and defined as being either inactive, moderately inactive, moderately active or active. 25 Alcohol intake was estimated as the average alcohol intake (in g/day) using a 24-hour dietary recall. Smoking status was defined as (1) never, (2) former, (3) current smoker and (4) unknown. Anthropometric measures were performed using standardised protocols, and body mass index (BMI) was calculated as weight in kilograms divided by squared height in metres (kg/m 2 ) and modelled as a continuous variable. In each centre, blood samples were collected at baseline, transferred to a local laboratory at 5°C-10°C while protected from light and, following processing, erythrocytes were stored in 0.5 mL straws at −196°C in liquid nitrogen. Samples for this study were retrieved and sent on dry ice to a central laboratory at University of Southampton, where they were analysed blinded to case/control status.
Time to diagnosis was defined as the time in years that had elapsed between date of blood sample and date of diagnosis, and was categorised in tertiles (years, median (range): first period: 2.77 (0.82-4.77); second period: 6.70 (4.94-7.99); third period: 10.07 (7.99-15) ).
Informed consent was given by all participants.
erythrocyte fatty acids
Total red cell lipids were extracted with chloroform and methanol (2:1, vol/vol) and dried under nitrogen. The total lipid extracts were dissolved in toluene, and fatty acid methyl esters (FAME) were synthesised by heating the purified lipids at 50°C in the presence of methanol containing 2% (v/v) sulfuric acid. FAMEs were recovered by extraction with hexane and resolved in a BPX-70 fused silica capillary column (32 m×0.25 mm×25 µm; SGE Analytical Science) using an Agilent 6890 gas chromatograph equipped with flame ionisation detection (Agilent Technologies). The relative concentrations (% of total) of individual fatty acids were calculated from the peak area using HP ChemStation (Agilent Technologies). Long-chain n-3 PUFAs were considered to be EPA, docosapentaenoic acid (22:5 n-3) and DHA. Using the fatty acid measurements, we calculated the sum of the total n-3 PUFA and total n-6 PUFA. Activities of desaturase enzymes, and in particular delta-6 desaturase (D6D), are considered to be rate-limiting steps in the conversion of the precursor n-3 PUFA ALA to the longer chain EPA and DHA, as well as in the parallel metabolism of n-6 PUFA. Activity of desaturase enzymes can be inferred from product to precursor ratios: 20:4 n-6/20:3 n-6 for delta-5 desaturase (D5D) and 18:3 n-6/18:2 n-6 for D6D. 26 27 
serum cytokines
The following cytokines were measured in serum by multispot assay following the manufacturer's instructions (Meso Scale Diagnostics, Rockville, USA): tumour necrosis factor alpha (TNFα), interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-13 and interferon gamma (IFNγ).
HLA-drb1 and autoantibodies
Human leucocyte antigen (HLA)-DRB1 gene full exon 2 DNA sequence was established using the Sanger method and sequence-specific oligonucleotide probes (SSOP) hybridisation used for quality assurance. HLA-DRB1 alleles considered to be shared epitope (SE)-positive, a major genetic risk factor for RA, were *0101, *0102, *0401, *0404, *0405, *0408, *0410, *1001, *1402 and *1406. IgM rheumatoid factor (RF) and anticitrullinated protein antibodies (ACPA; measured with an anti-cyclic citrullinated peptide 2 (CCP2) ELISA) were measured in baseline samples as previously described. 24 
statistical analysis
Fatty acids were categorised in tertiles based on their distribution in the control group, with the lowest category chosen as the referent. Variables with a non-normal distribution were log-transformed for analyses.
Fatty acid levels across the three time periods before RA diagnosis were compared using linear regression. Only one pre-RA subject had a diagnosis <1 year after blood sampling and exclusion of this case did not substantially change the results.
Confirmed pre-RA cases were matched with controls by age at blood collection (±1 year), sex, centre, date (±2 months) and time (±3 hours) of baseline blood collection, and fasting status at blood collection (<3/3-6/>6 hours).
We estimated the association with incident RA of each of the individual n-3 PUFA and n-6 PUFA, total n-3 PUFA, total n-6 PUFA and predefined ratios of PUFA variables.
Conditional logistic regression was conducted to estimate associations of PUFA with incident RA and obtain ORs and 95% CI, adjusting for potential confounders including BMI, waist circumference, education level, physical activity, smoking status and alcohol intake. We performed a complete case analysis. The proportion of subjects with missing data for covariates was <5%. In a sensitivity analysis, the model was further adjusted for the presence of HLA-DRB1 SE. The interaction between SE and LA was tested using multiplicative terms.
As a proinflammatory state may exist prior to the clinical onset of RA, and conceivably might alter PUFA metabolism, the relationship between PUFA levels and serum cytokines was analysed in the pre-RA and control groups separately. We also compared RF-positive pre-RA subjects to RF-negative matched controls using matched conditional logistic regression models, further adjusting for fewer potential confounders (ie, smoking status, alcohol intake, education level and SE) given the smaller sample size.
Given that the cytokine data were overdispersed, negative binomial regression was used to test the relationship between fatty acids (LA, total n-3 and n-6 PUFA, and the n-3:n-6 ratio) and serum cytokine levels, stratified by incident RA, adjusting for age, sex, country of origin, BMI and smoking status. The exponentiated regression coefficients (relative risk (RR)) were interpreted as a ratio of means. The RR indicates a positive or negative association between PUFA and cytokines. We used Stata software for statistical analyses. A P value less than 0.05 was considered as statistically significant. Formal alpha adjustments were not performed. Model 1: conditional logistic regression model matched by age at blood collection (±1 year), sex, centre, date (±2 months) and time (±3 hours) of baseline blood collection, and fasting status at blood collection (<3/3-6/>6 hours). There were erythrocyte samples available for 96 of the 103 pre-RA cases and 258 matched controls. Model 2 is model 1 with further adjustment for BMI, waist circumference, education level, physical activity, smoking status and alcohol intake. *The significance of linear trends across tertiles was tested with linear regression models. †Fatty acids are expressed as a percentage, median (IQR) of total erythrocyte membrane fatty acids. AA, arachidonic acid; ALA, alpha -linolenic acid ; BMI, body mass index; D5D, delta-5 desaturase activity inferred from product to precursor ratios; D6D, delta-6 desaturase activity inferred from product to precursor ratios; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; EPIC, European Prospective Investigation into Cancer and Nutrition; GLA, G amma -linolenic acid; LA, linoleic acid; LC PUFA: total longer chain n-3 PUFA; PUFA, polyunsaturated fatty acids; RA, rheumatoid arthritis.
The relationship between tertiles of n-3 and n-6 PUFA and risk of RA is shown in table 2. A significant inverse association was observed with the n-6 PUFA LA (highest tertile: OR 0.29; 95% CI 0.12 to 0.75; P for trend 0.01) and pre-RA in the fully adjusted model. However, no association was observed with any of the individual n-3 PUFA, total n-3 PUFA or total longchain n-3 PUFA, or with the total n-3:n-6 ratio. In a sensitivity analysis, a model with further adjustment for the presence of the HLA-DRB1 SE confirmed the significant inverse association with the n-6 PUFA LA and pre-RA (second tertile: OR 0.32; 95% CI 0.13 to 0.79; highest tertile: 0.21; 95% CI 0.07 to 0.67; P for trend 0.008). No interaction was observed between LA and the presence of the HLA-DRB1 SE (1 or 2 copies) in relation to risk for RA (P=0.68).
Longitudinal samples were not available, but we did compare pre-RA subjects across different time periods before diagnosis, and found a significant difference in the median PUFA membrane content of 20:3 n-6 and 22:5 n-3 with increasing levels closer to diagnosis (table 3) . Compared with the period of time immediately before the diagnosis (period 1), 20:3 n-6 and 22:5 n-3 were significantly lower in the period of time furthest away from diagnosis (period 3) (β −0.14, 95% CI −0.25 to −0.02, P=0.02; and β −0.25, 95% CI − 0.46 to −0.03, P=0.02, for 20:3 n-6 and 22:5 n-3, respectively). Conversely there was a trend for decreasing levels of LA closer to diagnosis (data for other PUFA not shown).
Because final autoantibody status was not known for all subjects, we did not compare the effects of PUFA on risk for autoantibody-positive versus autoantibody-negative RA. However, when restricting the analysis to pre-RA subjects who had documented RF postdiagnosis or a positive RF baseline sample (n=56 (58%)), compared with RF-negative matched controls (n=245 (96%)), an inverse association was also observed with LA for RF-positive pre-RA (lowest tertile: OR 1 (reference); second tertile: OR 0.18; 95% CI 0.03 to 0.96; highest tertile: OR 0.13; 95% CI 0.02 to 0.90; P for trend=0.04) in a multivariable-adjusted model.
The relationships between levels of LA, total n-3 and n-6 PUFA and the n-3:n-6 ratio and serum cytokines are displayed in online supplementary table 1 for the control population and  online supplementary table 2 for the pre-RA population. In the control population, LA was positively associated with levels of TNFα and IL-6 but negatively associated with IL-4, IL-5, IL-10, IL-12, IL-13 and IFNγ in fully adjusted models. In the pre-RA population, LA remained positively associated with TNFα and also IL-1, but was now negatively associated with IL-6. Negative associations between LA and IL-5, IL-12 and IL-13 persisted in the pre-RA group. The n-3:n-6 ratio was inversely associated with TNFα and IL-1 in both groups.
dIsCussIOn
We observed that erythrocyte membrane levels of the n-6 PUFA LA were inversely proportional to the risk of developing RA, whereas no protective effect was observed with n-3 PUFA. Previous studies have reported that a higher estimated intake of n-3 fatty acids may be protective against the development of RA in Swedish women, 18 and that erythrocyte n-3 levels were inversely related to the risk of RA-related autoimmunity in a population at risk of RA. 21 22 This discrepancy with our findings may first be explained by n-3 bioavailability, since previous research has shown lower long-chain n-3 PUFA blood levels in southern European populations compared with those from Scandinavia, 31 despite a similar estimated dietary intake of seafood n-3 PUFA. 32 In line with this, we observed mean erythrocyte levels of n-3 fatty acids in the control group that were lower than those observed in northern Sweden, with levels of EPA almost half (0.75% vs 1.4%). 33 34 Second, Gan et al 21 found that higher erythrocyte n-3 fatty acid levels were protective against RA-related autoimmunity only in patients who were HLA-DRB1 SE-positive, and hypothesised that this might be due to the ability of the n-3 PUFA DHA to alter lipid rafts and so influence antigen presentation by HLA molecules or regulatory T cell function. Notably, the prevalence of the SE is considerably higher in northern European RA populations compared with those from southern Europe (approaching 80% in some population-based studies 35 vs 44% in the pre-RA group studied here). We did, however, observe that higher levels of the n-6 PUFA LA were associated with lower risk for RA. LA was also negatively associated with RF positive RA, which overlaps considerably with the presence of ACPA, but no interaction was observed with the SE. A key question is whether LA is protective against RA, or whether lower LA levels in the pre-RA group are secondary to metabolic and inflammatory changes occurring before the clinical onset of RA. Interestingly, previous small studies in established RA have identified lower plasma phospholipid and adipose tissue LA relative to controls. 36 37 This was thought to be reverse causation, with a metabolic state in RA driving increased desaturase enzyme activity for which LA is a substrate. Indeed, we have previously suggested that D5D activity may be reduced following treatment with anti-TNF. 38 In this cohort we did not find D5D or D6D product to precursor ratios to be associated with risk of RA, or to vary with time to diagnosis, but we did observe a non-statistically significant trend for lower LA levels in subjects closest in time to RA diagnosis. Furthermore, we found increasing levels of 20:3 n-6 and 22:5 n-3 in subjects closest to diagnosis, compatible with increased production of downstream products from the metabolism of n-6 LA and n-3 ALA. Other published reports point to metabolic alterations occurring in the years before clinical onset of RA, including a reduction in total cholesterol and low-density lipoprotein and alterations in tryptophan metabolism. 39 40 Certainly reverse causation as an explanation of our LA findings would be more compatible with the widespread conception that n-6 PUFAs are proinflammatory. However the evidence to support this conception in humans in vivo is sparse. 41 Indeed, data from non-RA population-based studies have suggested that intake of n-6 PUFA is inversely associated with C-reactive protein (CRP) and certain proinflammatory cytokines. [42] [43] [44] [45] Furthermore, n-6 PUFA intake has been positively associated with levels of the anti-inflammatory cytokine transforming growth factor beta (TGFβ), 42 and n-6 PUFA supplementation in healthy volunteers increases TGFβ production by peripheral blood mononuclear cells ex vivo. 46 The n-6 PUFA arachidonic acid gives rise to prostaglandins and leucotrienes that are proinflammatory in a context-dependent fashion, but n-6 PUFA can also give rise to potent anti-inflammatory mediators such as lipoxins, 47 13-hydroxyoctadecadienoic acid 48 and nitrated-LA. 49 Higher doses of the longer chain n-6 PUFA gamma-linolenic acid were found in a small study to improve the signs and symptoms of RA. 50 Regarding other health outcomes, a meta-analysis of prospective studies on fatty acids and risk of coronary heart disease (CHD) observed an independent inverse association between LA and CHD risk (RR of CHD: 0.91; 95% CI 0.84 to 0.98). Other fatty acids were not associated with CHD. 51 More recently, the Cardiovascular Health Study, a community-based US cohort of 2792 participants aged 65 years and older free of CVD at baseline, observed that high circulating LA, but not other n-6 PUFA, was inversely associated with total and CHD mortality. 52 A recent large cohort study including over 27 000 participants in the EPIC-InterAct study across European countries observed that LA is inversely associated with type 2 diabetes (T2D). The results also suggested an inverse association of ALA but no convincing association of marine-derived n-3 PUFA with T2D. 27 Also a recent large pooled analysis of individual-level data for nearly 40 000 adults from 20 prospective studies has shown that higher levels of LA biomarkers were independently associated with a lower risk of T2D. 53 Given our findings on LA and risk of RA, we explored the relationship of LA and serum cytokines in this population. The observed positive association between LA and TNFα and IL-6 in our control group is consistent with the hypothesis that high n-6 PUFA and LA are proinflammatory, and the n-3:n-6 ratio was inversely associated with TNFα and IL-1 levels in both the controls and the pre-RA group. Also in support of inflammation driving a reduction in LA is the shift from a positive association between LA and IL-6 in the control population, to a negative association in the pre-RA group, although interestingly both TNFα and IL-1 remain positively associated with LA in pre-RA. Also consistent with prevailing notions is our finding of a negative association between LA and Th2 cytokines IL-4, IL-5 and IL-13, and also IL-10, which is produced by monocytes and to a lesser extent Th2 cells, and has well-established anti-inflammatory functions. However LA was also negatively associated with IL-12, which induces Th1 responses, and also the Th1 cytokine IFNγ, implying more generally downregulated T cell function. The important role of T cells in the pathogenesis of RA, and the observation that high levels of Th2 cytokines have been shown in the earliest phase of the disease, 54 could support the hypothesis of high LA levels being protective in this population. Furthermore, polymorphisms in the fatty acid desaturase (FADS) genes, which encode the rate-limiting enzymes for the biosynthesis of longer chain n-6 and n-3 PUFA, have been identified as being risk factors for RA, suggesting that PUFA status may contribute to RA pathogenesis. 55 The strengths of the present study are the large number of matched controls and pre-RA cases from a population-based cohort and measurement of erythrocyte PUFA and cytokines in samples taken prior to clinical onset of RA. The measure of objective biomarkers allowed investigation of individual PUFA while avoiding potential errors and recall bias related to self-reported dietary intake. Indeed total erythrocyte n-3 PUFA status did not correlate with fish intake in this cohort (data not shown).
We also took careful control of important potential confounding factors. However, residual and unmeasured confounding remains an important limitation; this may be particularly relevant to studies of specific nutrients, which themselves are part of more complex dietary intake.
The analyses of associations between PUFA and incident RA involved multiple tests of significance. A potential limitation relates to multiple testing, because multiple comparisons are associated with an increased chance for a type I error. However, the utility of formal adjustments for multiple comparisons in an epidemiological context has been questioned. [28] [29] [30] We therefore chose not to perform any formal alpha adjustments in the present study and acknowledge the need to consider with caution the statistical significance of such associations.
In conclusion, we found erythrocyte levels of LA, the major dietary n-6 PUFA, were inversely associated with risk of pre-RA. Other n-6 PUFA and n-3 PUFA were not significantly associated with risk of RA. Further work is warranted to replicate these findings and to investigate if LA is protective against RA development or if lower levels are secondary to metabolic and inflammatory changes occurring before the clinical onset of RA. Contributors BAF, dr, dSM, Er and pV conceived the study. pdp performed statistical analysis. All other authors contributed to the generation of data. BAF drafted the manuscript, which was reviewed and revised by all authors.
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